Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190

Watchlist Manager
Zylox-Tonbridge Medical Technology Co Ltd Logo
Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190
Watchlist
Price: 15.9 HKD 2.45% Market Closed
Market Cap: 5.2B HKD
Zylox-Tonbridge Medical Technology Co Ltd
/
Income Statement
/
Interest Income Expense

Zylox-Tonbridge Medical Technology Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zylox-Tonbridge Medical Technology Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190
Interest Income Expense
¥69.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Interest Income Expense
¥18m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Interest Income Expense
¥231.5m
CAGR 3-Years
154%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Interest Income Expense
¥637.1m
CAGR 3-Years
126%
CAGR 5-Years
14%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Interest Income Expense
-¥75.4m
CAGR 3-Years
52%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Interest Income Expense
¥257.2m
CAGR 3-Years
190%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Zylox-Tonbridge Medical Technology Co Ltd
Glance View

Market Cap
5.2B HKD
Industry
Health Care

Zylox-Tonbridge Medical Technology Co., Ltd. operates as a medical devices company. The company is headquartered in Hangzhou, Zhejiang and currently employs 487 full-time employees. The company went IPO on 2021-07-05. The firm's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB). The firm's products are sold to domestic and foreign markets.

Intrinsic Value
19.22 HKD
Undervaluation 17%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Zylox-Tonbridge Medical Technology Co Ltd's Interest Income Expense?
Interest Income Expense
69.5m CNY

Based on the financial report for Dec 31, 2023, Zylox-Tonbridge Medical Technology Co Ltd's Interest Income Expense amounts to 69.5m CNY.

What is Zylox-Tonbridge Medical Technology Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-42%

Over the last year, the Interest Income Expense growth was -42%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.